The biology of lung cancer including potential clinical applications

S. Zochbauer-Muller, J. D. Minna

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The understanding of lung cancer pathogenesis is rapidly growing and needs to be translated into clinical practice. Molecular screening approaches will be combined with CT scans to detect premalignant lesions and early-stage cancers in high-risk groups for lung cancer and to monitor the efficacy of chemoprevention trials. New treatment approaches, such as gene therapy, monoclonal antibodies against growth factors and receptors, angiogenesis inhibitors, vaccines, apoptosis modulators, and new drugs targeted at these abnormal pathways, will be tested and, if effective, included in future multimodality treatment strategies of lung cancer. All these approaches will hopefully lead to earlier diagnosis and more efficient treatment of lung cancer, resulting in a better prognosis of this still mostly lethal disease.

Original languageEnglish (US)
Pages (from-to)691-708
Number of pages18
JournalChest Surgery Clinics of North America
Volume10
Issue number4
StatePublished - 2000

Fingerprint

Lung Neoplasms
Angiogenesis Inhibitors
Growth Factor Receptors
Chemoprevention
Genetic Therapy
Early Diagnosis
Therapeutics
Vaccines
Monoclonal Antibodies
Apoptosis
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The biology of lung cancer including potential clinical applications. / Zochbauer-Muller, S.; Minna, J. D.

In: Chest Surgery Clinics of North America, Vol. 10, No. 4, 2000, p. 691-708.

Research output: Contribution to journalArticle

@article{a0ac22612cfe4eb2921418e9b6e1ff72,
title = "The biology of lung cancer including potential clinical applications",
abstract = "The understanding of lung cancer pathogenesis is rapidly growing and needs to be translated into clinical practice. Molecular screening approaches will be combined with CT scans to detect premalignant lesions and early-stage cancers in high-risk groups for lung cancer and to monitor the efficacy of chemoprevention trials. New treatment approaches, such as gene therapy, monoclonal antibodies against growth factors and receptors, angiogenesis inhibitors, vaccines, apoptosis modulators, and new drugs targeted at these abnormal pathways, will be tested and, if effective, included in future multimodality treatment strategies of lung cancer. All these approaches will hopefully lead to earlier diagnosis and more efficient treatment of lung cancer, resulting in a better prognosis of this still mostly lethal disease.",
author = "S. Zochbauer-Muller and Minna, {J. D.}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "691--708",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The biology of lung cancer including potential clinical applications

AU - Zochbauer-Muller, S.

AU - Minna, J. D.

PY - 2000

Y1 - 2000

N2 - The understanding of lung cancer pathogenesis is rapidly growing and needs to be translated into clinical practice. Molecular screening approaches will be combined with CT scans to detect premalignant lesions and early-stage cancers in high-risk groups for lung cancer and to monitor the efficacy of chemoprevention trials. New treatment approaches, such as gene therapy, monoclonal antibodies against growth factors and receptors, angiogenesis inhibitors, vaccines, apoptosis modulators, and new drugs targeted at these abnormal pathways, will be tested and, if effective, included in future multimodality treatment strategies of lung cancer. All these approaches will hopefully lead to earlier diagnosis and more efficient treatment of lung cancer, resulting in a better prognosis of this still mostly lethal disease.

AB - The understanding of lung cancer pathogenesis is rapidly growing and needs to be translated into clinical practice. Molecular screening approaches will be combined with CT scans to detect premalignant lesions and early-stage cancers in high-risk groups for lung cancer and to monitor the efficacy of chemoprevention trials. New treatment approaches, such as gene therapy, monoclonal antibodies against growth factors and receptors, angiogenesis inhibitors, vaccines, apoptosis modulators, and new drugs targeted at these abnormal pathways, will be tested and, if effective, included in future multimodality treatment strategies of lung cancer. All these approaches will hopefully lead to earlier diagnosis and more efficient treatment of lung cancer, resulting in a better prognosis of this still mostly lethal disease.

UR - http://www.scopus.com/inward/record.url?scp=0033758496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033758496&partnerID=8YFLogxK

M3 - Article

C2 - 11091920

AN - SCOPUS:0033758496

VL - 10

SP - 691

EP - 708

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 4

ER -